Acamprosate

Bibliography

• World Health Organization. The World Health Report 2003. Geneva, Switzerland
   Google Scholar
• Regier DA, Farmer ME, Rae DS, Comorbidity of mental disorders with alcohol and other drug abuse: results for the Epidemiologic Catchment Area Study. JAMA 1990;264:2511-18
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). 2002 – 2004 National Survey on Drug Use and Health (NSDUH). Rockville, MD
   Google Scholar
• Grant BF, Dawson DA. The 12-Month Prevalence and Trends in DSM–IV Alcohol Abuse and Dependence: United States, 1991 – 1992 and 2001 – 2002. Alcohol Res Health 2006;29:79-93
   Google Scholar
• Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data. Report prepared by The Lewin Group for the National Institute on Alcohol Abuse and Alcoholism, 2000
   Google Scholar
• Barnard EA, Skolnick P, International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric-acid-a receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998;50(2):291-313
   PubMed Web of Science ®Google Scholar
• Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009;10(8):561-72
   PubMed Web of Science ®Google Scholar
• Doer PL, Kennedy WK, Boothby LA. Substance related disorders: alcohol, nicotine, and caffeine in pharmacotherapy (Chapter 69). In: DiPiro, Talbert, Yee, et al, editors, A pathophysiologic approach. 7th edition. ISBN: 9780071416139; McGraw Hill Medical Publishing; 2008
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, version IV text revision. APA Press, 2000
   Google Scholar
• Miller WR, Wilbourne PL, Hettema JE. What works? A summary of alcohol treatment outcome research. In: Hester RK, Miller WR, editors, Handbook of alcoholism treatment approaches: effective alternatives. 3rd edition. Pearson Education, Inc., Boston MA; 2003. p. 13-63
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, 2nd edition. In American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. Arlington, VA: American Psychiatric Association; 2006. p. 291-563). Available from: http://www.psych.org/psych_pract/treatg/pg/SUD2ePG_04-28-06.pdf
   Google Scholar
• Campral [package insert]. Forest Pharmaceuticals, Inc. St Louis, Mo; 2005
   Google Scholar
• Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987;4:97-102
   PubMed Web of Science ®Google Scholar
• De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005;19:517-37
   PubMed Web of Science ®Google Scholar
• Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 2008;29:109-15
   PubMed Web of Science ®Google Scholar
• Dahchour A, De Witte P, Bolo N, Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 1998;82:107-14
   PubMed Web of Science ®Google Scholar
• Littleton J. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med 2007;1:115-25
   PubMed Web of Science ®Google Scholar
• Chau P, Höifödt-Lidö H, Löf E, Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate. Alcohol Clin Exp Res 2009 [Epub ahead of print]
   Google Scholar
• Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997;18:54-9
   PubMed Web of Science ®Google Scholar
• Johnson B, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000;149:327-44
   PubMed Web of Science ®Google Scholar
• Johnson B. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008;75(1):34-56
   PubMed Web of Science ®Google Scholar
• Mann K, Kiefer F, Spanagel, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008;32(7):1105-10
   PubMed Web of Science ®Google Scholar
• Brasser SM, McCaul ME, Houtsmuller EJ. Alcohol effects during acamprosate treatment: a dose-response study in humans. Alcohol Clin Exp Res 2004;28(7):1074-83
   PubMed Web of Science ®Google Scholar
• Johnson B, O'Malley S, Ciraulo D, Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 2003;23:281-93
   PubMed Web of Science ®Google Scholar
• Hammarberg A, Jayaram-Lindström N, Beck O, The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology 2009;205:53-62
   PubMed Web of Science ®Google Scholar
• Mason B, Goodman A, Dixon R, A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606
   PubMed Web of Science ®Google Scholar
• Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother 2005;6(12):2103-15
   PubMed Web of Science ®Google Scholar
• Saivin S, Hulot T, Chabac S, Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35(5):331-45
   PubMed Web of Science ®Google Scholar
• Pelc I, Verbanck P, Le Bon O, Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997;171:73-7
   PubMed Web of Science ®Google Scholar
• Sass H, Soyka M, Mann K, Zieglgänsberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53(8):673-80
   PubMed Web of Science ®Google Scholar
• Paille GM, Fuelfi JD, Perkins AC, Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995;30:239-47
   PubMed Web of Science ®Google Scholar
• Mann K, Lehert P, Morgan M. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004;28(1):51-63
   PubMed Web of Science ®Google Scholar
• Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006;40(5):383-93
   PubMed Web of Science ®Google Scholar
• Kampman K, Pettinati H, Lynch K, Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav 2009;34:581-6
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T, Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60(1):92-9
   PubMed Web of Science ®Google Scholar
• Anton RF, O'Malley SS, Ciraulo DA, COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295(17):2003-17
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Selby P, Negrete J. Meta-analysis of placebo-controlled trials of acamprosate for the treatment of alcohol dependence. Impact of the combined pharmacotherapies and behavior interventions study. J Addict Med 2009;3(2):74-82
   PubMed Web of Science ®Google Scholar
• Kiefer F, Helwig H, Tarnaske T, Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 2005;11:83-91
   PubMed Web of Science ®Google Scholar
• Lesch OM, Riegler A, Gutierrez K, The European acamprosate trials: conclusions for research and therapy. J Biomed Sci 2001;8(1):89-95
   PubMed Web of Science ®Google Scholar
• Verheul R, Lehert P, Geerlings P, Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 2005;178:167-73
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Gage A, Perhach JL, Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med 2008;2(1):40-50
   PubMed Web of Science ®Google Scholar
• Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav 1989;32(3):607-11
   PubMed Web of Science ®Google Scholar
• Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 2003;13(6):469-75
   PubMed Web of Science ®Google Scholar
• Morley KC, Teesson M, Reid SC, Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101(10):1451-62
   PubMed Web of Science ®Google Scholar
• Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol 2004;65(1):136-9
   PubMed Web of Science ®Google Scholar
• Namkoong K, Lee BO, Lee PG, Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003;38(2):135-41
   PubMed Web of Science ®Google Scholar
• Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001;36(5):413-8
   PubMed Web of Science ®Google Scholar
• Tempesta E, Janiri L, Bignamini A, Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000;35(2):202-9
   PubMed Web of Science ®Google Scholar
• Chick J, Howlett H, Morgan MY, United kingdom multicenter acamprosate study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35(2):176-87
   PubMed Web of Science ®Google Scholar
• Besson J, Aeby F, Kasas A, Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998;22(3):573-9
   PubMed Web of Science ®Google Scholar
• Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997;92(11):1537-46
   PubMed Web of Science ®Google Scholar
• Geerlings PJ, Ansoms C, Van den Brink W. Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled double-blind study in out-patient alcoholics in the Netherlands, Belgium, and Luxembourg. Eur Addict Res 1997;3:129-37
   Web of Science ®Google Scholar
• Whitworth AB, Fischer F, Lesch OM, Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347(9013):1438-42
   PubMed Web of Science ®Google Scholar
• Kiefer F, Andersohn F, Otte C, Long-term effect of pharmacotherapy on relapse prevention in alcohol dependence. Acta Neuropsychiatr 2004;16:233-8
   PubMed Web of Science ®Google Scholar
• Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 2003;12(3):144-8
   PubMed Web of Science ®Google Scholar